Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Non-cancer drugs repurposing, a new trick to win the onco-challenge?
  • News

Non-cancer drugs repurposing, a new trick to win the onco-challenge?

  • 3 February 2020
  • Cristina Ferrario
Non-cancer drugs repurposing, a new trick to win the onco-challenge?
Total
0
Shares
0
0
0
0
0

Originally developed and approved for use in diabetes, inflammation and other non-oncological diseases (even osteoarthritis in dogs), many drugs could have a pivotal role in treating cancer. And they could be more abundant than expected, according to a paper recently published in Nature Cancer.

“Anticancer uses of non-oncology drugs have occasionally been found, but such discoveries have been serendipitous” wrote the authors, led by Steven Corsello, medical oncologist at the Dana-Farber Cancer Institute (Boston). Corsello is the founder of the Drug Repurposing Hub at the Broad Institute of MIT and Harvard, an information resource providing extensive annotations for thousands of drugs. He and colleagues systematically tested 4,518 drug compounds from the above-mentioned Drug Repurposing Hub across 578 human cancer cell lines, evaluating their effects on cell viability.

For this screening, researchers used a molecular barcoding method called PRISM (profiling relative inhibition simultaneously in mixtures), recovering almost 50 non-oncology compounds with previously unknown selective anticancer activity, predictable by the molecular characteristics of the cell line. Interestingly, the analysis also revealed new targets and molecular mechanisms of action, paving the way to the development of new anticancer drugs.

Moving from experimental to clinical settings, authors reminded that the ability to kill cancer cells shown by some non-oncology compounds does not mean that they could be immediately tested in cancer patients. “The PRISM results reported in this study represent starting points for new drug development. When the anticancer activity of a drug occurs via an off-target mechanism, it is probable that further optimization for this new target will result in more potent and selective drug candidates” experts explained.

“Further development of such compounds as repurposed cancer drugs will probably require extensive chemical and pharmacological optimization and validation, but this unbiased multi-platform approach does provide a unique starting point for future efforts” confirmed Roderick L. Beijersbergen, NKI Robotics and Screening Center, The Netherlands Cancer Institute, Amsterdam in a commentary.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • drug repurposing
  • hub
  • repurposing
Cristina Ferrario

Previous Article
  • News

Genetics of breast cancer: much more than a BRCA story

  • 27 January 2020
  • Elena Riboldi
View Post
Next Article
  • Editorials

Tackling cancer in interesting times

  • 4 February 2020
  • Adriana Albini
View Post
You May Also Like
View Post
  • Articles
  • News

CancerWorld issue #103 (May, 2025)

  • Yeva Margaryan
  • 11 May 2025
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Janet Fricker
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Janet Fricker
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Janet Fricker
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • CancerWorld issue #103 (May, 2025)
    • 11 May 2025
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
Article
  • Why Patient-Reported Outcomes are Rarely Used in Trials, and How We Change That
    • 27 May 2025
  • A Promise Kept: How Samvel Danielyan Lifted Pediatric Cancer Survival from Zero to 70%
    • 25 May 2025
  • Together, She Changed Everything: Martine Piccart ’s Fight Against Breast Cancer
    • 20 May 2025
Social

Would you follow us ?

Contents
  • A Promise Kept: How Samvel Danielyan Lifted Pediatric Cancer Survival from Zero to 70%
    • 25 May 2025
  • Together, She Changed Everything: Martine Piccart ’s Fight Against Breast Cancer
    • 20 May 2025
  • Adrian Gottschalk: Making a Difference for His Fellow Human Beings
    • 10 May 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.